Restricted accessResearch articleFirst published online 2021-06
Safety,Immune,and Antiviral Effects of Pegylated Interferon Alpha 2b Administration in Antiretroviral Therapy-Suppressed Individuals: Results of Pilot Clinical Trial
In the pilot NCT01935089 trial, we tested whether pegylated interferon alpha2b (Peg-IFN-α2b) with antiretroviral therapy (ART) was safe and could impact HIV and immune measures in blood and in gut-associated lymphoid tissue (GALT). Twenty HIV-1+ ART-suppressed individuals received 1 μg/kg/week Peg-IFN-α2b with ART for 20 weeks, with intermediate 4-week analytical ART interruption (ATI). Safety, immune activation, HIV viral load and integrated HIV DNA in blood, and HIV RNA and DNA in gut biopsies were measured. A total of 7/20 participants experienced grade 3–4 adverse events, while 17/20 participants completed the study. Of the 17 participants who completed the study, 8 remained suppressed during ATI, while all 17 were suppressed at end of treatment (EoT). As expected, treatment increased activation of T and natural killer (NK) cells and IFN-stimulated molecule expression on monocytes in periphery. While circulating CD4+ T cells showed a trend for a decrease in integrated HIV DNA, GALT showed a significant decrease in HIV-1 RNA+ cells as measured by in situ hybridization along with a reduction in total HIV DNA and cell-associated RNA by EoT. The observed decrease in HIV-1 RNA+ cells in GALT was positively associated with the decrease in activated NK cells and macrophages. This study documents for the first time that 20 weeks of immunotherapy with Peg-IFN-α2b+ART (inclusive of a 4-week ATI) is safe and results in an increase in blood and GALT immune activation and in a significant decrease in HIV-1 RNA+ cells in GALT in association with changes in innate cell activation.
Get full access to this article
View all access options for this article.
References
1.
ChunTW, CarruthL, FinziD, et al.: Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature, 1997; 387:183–188.
2.
ChunTW, FinziD, MargolickJ, ChadwickK, SchwartzD, SilicianoRF: In vivo fate of HIV-1-infected T cells: Quantitative analysis of the transition to stable latency. Nat Med, 1995; 1:1284–1290.
3.
CoirasM, Lopez-HuertasMR, Perez-OlmedaM, AlcamiJ: Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs. Nat Rev Microbiol, 2009; 7:798–812.
4.
ColinL, Van LintC: Molecular control of HIV-1 postintegration latency: Implications for the development of new therapeutic strategies. Retrovirology, 2009; 6:111.
5.
DahlV, JosefssonL, PalmerS: HIV reservoirs, latency, and reactivation: Prospects for eradication. Antiviral Res, 2010; 85:286–294.
6.
Fernandez-GonzalezM, GarciaJA, PadillaS, et al.: Rectal and seminal HIV-1 RNA decay towards virological suppression in infected MSM initiating dolutegravir/abacavir/lamivudine. J Antimicrob Chemother, 2020; 75:668–674.
7.
HatanoH, SomsoukM, SinclairE, et al.: Comparison of HIV DNA and RNA in gut-associated lymphoid tissue of HIV-infected controllers and noncontrollers. AIDS, 2013; 27:2255–2260.
8.
LahiriCD, BrownNL, RyanKJ, et al.: HIV RNA persists in rectal tissue despite rapid plasma virologic suppression with dolutegravir-based therapy. AIDS, 2018; 32:2151–2159.
9.
SnellerMC, HuitingED, ClarridgeKE, et al.: Kinetics of plasma HIV rebound in the era of modern antiretroviral therapy. J Infect Dis, 2020; ;222:1655–1659.
10.
Le PageC, GeninP, BainesMG, HiscottJ: Interferon activation and innate immunity. Rev Immunogenet, 2000; 2:374–386.
11.
PapasavvasE, FoulkesA, YinX, et al.: Plasmacytoid dendritic cell and functional HIV Gag p55-specific T cells before treatment interruption can inform set-point plasma HIV viral load after treatment interruption in chronically suppressed HIV-1(+) patients. Immunology, 2015; 145:380–390.
12.
TomescuC, LiuQ, RossBN, et al.: A correlate of HIV-1 control consisting of both innate and adaptive immune parameters best predicts viral load by multivariable analysis in HIV-1 infected viremic controllers and chronically-infected non-controllers. PLoS One, 2014; 9:e103209.
13.
TomescuC, ChehimiJ, MainoVC, MontanerLJ: NK cell lysis of HIV-1-infected autologous CD4 primary T cells: Requirement for IFN-mediated NK activation by plasmacytoid dendritic cells. J Immunol, 2007; 179:2097–2104.
14.
HarperMS, GuoK, GibbertK, et al.: Interferon-alpha subtypes in an ex vivo model of acute HIV-1 infection: Expression, potency and effector mechanisms. PLoS Pathog, 2015; 11:e1005254.
15.
SutterK, DickowJ, DittmerU: Interferon alpha subtypes in HIV infection. Cytokine Growth Factor Rev, 2018; 40:13–18.
16.
AkiyamaH, RamirezNP, GibsonG, et al.: Interferon-inducible CD169/Siglec1 attenuates anti-HIV-1 effects of alpha interferon. J Virol, 2017; 91:e00972–17.
17.
GeorgeJ, MattapallilJJ: Interferon-alpha subtypes as an adjunct therapeutic approach for human immunodeficiency virus functional cure. Front Immunol, 2018; 9:299.
18.
AzzoniL, FoulkesAS, PapasavvasE, et al.: Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration. J Infect Dis, 2013; 207:213–222.
19.
PapasavvasE, AzzoniL, KossenkovAV, et al.: NK response correlates with HIV decrease in pegylated IFN-alpha2a-treated antiretroviral therapy-suppressed subjects. J Immunol, 2019; 203:705–717.
20.
JiaoYM, WengWJ, GaoQS, et al.: Hepatitis C therapy with interferon-alpha and ribavirin reduces the CD4 cell count and the total, 2LTR circular and integrated HIV-1 DNA in HIV/HCV co-infected patients. Antiviral Res, 2015; 118:118–122.
21.
SunH, BuzonMJ, ShawA, et al.: Hepatitis C therapy with interferon-alpha and ribavirin reduces CD4 T-cell-associated HIV-1 DNA in HIV-1/hepatitis C virus-coinfected patients. J Infect Dis, 2014; 209:1315–1320.
22.
HuaS, ViganoS, TseS, et al.: Pegylated interferon-alpha-induced natural killer cell activation is associated with human immunodeficiency virus-1 DNA decline in antiretroviral therapy-treated HIV-1/hepatitis C virus-coinfected patients. Clin Infect Dis, 2018; 66:1910–1917.
23.
StevensonJP, KindlerHL, PapasavvasE, et al.: Immunological effects of the TGFbeta-blocking antibody GC1008 in malignant pleural mesothelioma patients. Oncoimmunology, 2013; 2:e26218.
24.
CaligiuriMA: Human natural killer cells. Blood, 2008; 112:461–469.
25.
LongEO, KimHS, LiuD, PetersonME, RajagopalanS: Controlling natural killer cell responses: Integration of signals for activation and inhibition. Annu Rev Immunol, 2013; 31:227–258.
26.
CollinM, McGovernN, HaniffaM: Human dendritic cell subsets. Immunology, 2013; 140:22–30.
27.
GrafEH, MexasAM, YuJJ, et al.: Elite suppressors harbor low levels of integrated HIV DNA and high levels of 2-LTR circular HIV DNA compared to HIV+ patients on and off HAART. PLoS Pathog, 2011; 7:e1001300.
28.
MexasAM, GrafEH, PaceMJ, et al.: Concurrent measures of total and integrated HIV DNA monitor reservoirs and ongoing replication in eradication trials. AIDS, 2012; 26:2295–2306.
YuanZ, KangG, MaF, et al.: Recapitulating cross-species transmission of simian immunodeficiency virus SIVcpz to humans by using humanized BLT mice. J Virol, 2016; 90:7728–7739.
31.
SalantesDB, ZhengY, MampeF, et al.: HIV-1 latent reservoir size and diversity are stable following brief treatment interruption. J Clin Invest, 2018; 128:3102–3115.
32.
ColliML, HillJLE, MarroquiL, et al.: PDL1 is expressed in the islets of people with type 1 diabetes and is up-regulated by interferons-alpha and-gamma via IRF1 induction. EBioMedicine, 2018; 36:367–375.
33.
StaplesKJ, NicholasB, McKendryRT, et al.: Viral infection of human lung macrophages increases PDL1 expression via IFNbeta. PLoS One, 2015; 10:e0121527.
34.
NoureddinM, GhanyMG: Pharmacokinetics and pharmacodynamics of peginterferon and ribavirin: Implications for clinical efficacy in the treatment of chronic hepatitis C. Gastroenterol Clin North Am, 2010; 39:649–658.
35.
CalicetiP: Pharmacokinetics of pegylated interferons: What is misleading?. Dig Liver Dis, 2004; 36Suppl 3:S334–S339.
36.
FosterGR: Pegylated interferons for the treatment of chronic hepatitis C: Pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b. Drugs, 2010; 70:147–165.
37.
MarkovaAA, MihmU, SchlaphoffV, et al.: PEG-IFN alpha but not ribavirin alters NK cell phenotype and function in patients with chronic hepatitis C. PLoS One, 2014; 9:e94512.
38.
ShenX, FuB, LiuY, et al.: NKp30+ NK cells are associated with HBV control during pegylated-interferon-alpha-2b therapy of chronic hepatitis B. Sci Rep, 2016; 6:38778.
39.
NeilSJ, ZangT, BieniaszPD: Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature, 2008; 451:425–430.
40.
Van DammeN, GoffD, KatsuraC, et al.: The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe, 2008; 3:245–252.
41.
PuryearWB, AkiyamaH, GeerSD, et al.: Interferon-inducible mechanism of dendritic cell-mediated HIV-1 dissemination is dependent on Siglec-1/CD169. PLoS Pathog, 2013; 9:e1003291.
42.
AppasamyR, BryantJ, HassaneinT, Van ThielDH, WhitesideTL: Effects of therapy with interferon-alpha on peripheral blood lymphocyte subsets and NK activity in patients with chronic hepatitis C. Clin Immunol Immunopathol, 1994; 73:350–357.
43.
ManionM, RodriguezB, MedvikK, et al.: Interferon-alpha administration enhances CD8+ T cell activation in HIV infection. PLoS One, 2012; 7:e30306.
44.
PortalesP, ReynesJ, PinetV, et al.: Interferon-alpha restores HIV-induced alteration of natural killer cell perforin expression in vivo. AIDS, 2003; 17:495–504.
45.
PortalesP, ReynesJ, Rouzier-PanisR, BaillatV, ClotJ, CorbeauP: Perforin expression in T cells and virological response to PEG-interferon alpha2b in HIV-1 infection. AIDS, 2003; 17:505–511.
46.
TomescuC, MavilioD, MontanerLJ: Lysis of HIV-1-infected autologous CD4+ primary T cells by interferon-alpha-activated NK cells requires NKp46 and NKG2D. AIDS, 2015:29:1767–1773.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
